Skip to main content

Table 3 Prediction for infection(only patients with Cancer)

From: One-year mortality and Periprosthetic infection rates after Total knee Arthroplasty in Cancer patients: a population-based cohort study

Ā 

Adjusted

sHRa(95%C.I.)

p-value

Comorbidities

ā€ƒMyocardial infarct

ā€“

Ā 

ā€ƒcongestive heart failure

1.21 (0.45ā€“3.26)

0.7122

ā€ƒperipheral vascular

1.58 (0.36ā€“7.02)

0.5493

ā€ƒcerebrovascular disease

1.65 (0.78ā€“3.48)

0.1866

ā€ƒdementia

2.81 (0.80ā€“9.85)

0.1060

ā€ƒchronic lung disease

0.76 (0.37ā€“1.56)

0.4507

ā€ƒconnective tissue disease

1.80 (0.63ā€“5.20)

0.2757

ā€ƒUlcer

1.59 (0.81ā€“3.12)

0.1759

ā€ƒchronic liver disease

1.12 (0.46ā€“2.72)

0.7990

ā€ƒDiabetes

0.78 (0.33ā€“1.81)

0.5613

ā€ƒdiabetes with end organ damage

1.87 (0.47ā€“7.52)

0.3770

ā€ƒHemiplegia

1.92 (0.24ā€“15.21)

0.5363

ā€ƒmoderate or severe kidney disease

0.94 (0.28ā€“3.14)

0.9147

Moderate or severe liver disease

AIDS

ā€ƒChemotherapy

1.02 (0.49ā€“2.14)

0.9608

ā€ƒMetastasis

11.10 (1.22ā€“101.30)

0.0328

  1. sHRa: subdistribution hazard ratio